1 Follow-Up Q & A Webinar: Opioid Use Disorders: The Female Experience Ashley Braun-Gabelman, Ph.D. University Hospitals Case Medical Center
1
Follow-Up Q & A Webinar:
Opioid Use Disorders: The Female Experience
Ashley Braun-Gabelman, Ph.D.
University Hospitals Case Medical Center
2
Ashley Braun-Gabelman, Disclosures
• No disclosures
3
Planning Committee, Disclosures
AAAP aims to provide educational information that is balanced, independent, objective and free of bias
and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information
from all planners, faculty and anyone in the position to control content is provided during the planning
process to ensure resolution of any identified conflicts. This disclosure information is listed below:
The following developers and planning committee members have reported that they have no
commercial relationships relevant to the content of this webinar to disclose: AAAP CME/CPD
Committee Members Dean Krahn, MD, Kevin Sevarino, MD, PhD, Tim Fong, MD, Tom Kosten,
MD, Joji Suzuki, MD; and AAAP Staff Kathryn Cates-Wessel, Miriam Giles, and Justina Andonian.
All faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is
accepted within the profession of medicine as adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally
accepted standards of experimental design, data collection, and analysis. The content of this CME activity has been
reviewed and the committee determined the presentation is balanced, independent, and free of any commercial bias.
Speakers must inform the learners if their presentation will include discussion of unlabeled/investigational use of
commercial products.
4
Target Audience
• The overarching goal of PCSS-O is to offer evidence-based
trainings on the safe and effective prescribing of opioid medications
in the treatment of pain and/or opioid addiction.
• Our focus is to reach providers and/or providers-in-training from
diverse healthcare professions including physicians, nurses,
dentists, physician assistants, pharmacists, and program
administrators.
5
Educational Objectives
• At the conclusion of this activity participants should
be able to:
▪ Identify changing demographics of heroin and
opioid use disorders
▪ Recognize barriers to treatment
▪ Discuss gender-related treatment issues
▪ Describe co-occurring disorders
▪ Identify treatment options for pregnant women
6
Outline
• Changing demographics of OUD
• Course of illness
• Treatment issues
▪ Barriers to treatment
• Co-occurring disorders
• Pregnancy
7
Case Vignette #1: Kelly
• Caucasian, 45 y/o presents with Heroin Use
Disorder, severe
• Childhood sexual abuse, incest, poverty, neglect
• Strong family h/o addiction
• First given tramadol by brother
▪ “Mother’s little helper”
8
Case Vignette #1: Kelly
• Now self-described “Soccer Mom”
▪ Married mother of 2 teenage daughters
▪ Manager at work
▪ “I needed to use to be able to get everything
done.”
9
Case Vignette #2: Jessica
• 36 y/o, Caucasian, single mother of 3 y/o son and
8 y/o daughter
• Works as RN
• Nominated for “Nurse of the Year Award”
• Diverting Oxycodone from work
• Mother recovering alcoholic
• “The pills made me feel competent, energetic.”
10
Changing Demographics of Opiate Users
• Currently, about 1/3 of those with opioid dependence are women of child-bearing age (Unger et al. 2010)
• January 17, 2016 NY Times: The death rates of Caucasians,
especially women, are rising (death rates for black and Hispanics continue to fall)
• Drug overdose • New users predominantly white, living in nonurban
areas • 75% current heroin users began with Rx opioids
first
11
Epidemiology
• The demographics of those who abuse heroin and other opiates has changed in recent years (Cicero, 2014)
− 1960s: mostly men abusing heroin
− Now: men and women
Cicero, Ellis, Surratt, Kurtz (2014)
12
Prescription Opioids
• Mixed findings
▪ Several large scale studies found women more likely
to use and abuse prescription opioids (CDC, 2016; Green et al., 2009,
Rosenblum et al., 2007; Simoni-Wastila et al., 2000,2004, c.f. Back et al., 2010
▪ In contrast, 2013 and 2014 NSDUH nonmedical use
of pain medication still higher among men
• Rx misuse and overdose among women rapidly rising
13
Rx Opioids
• In the past two decades, opioid prescriptions have increased overall
• Women tend to be prescribed medication with abuse potential more often than men (Isacson and Bingefors, 2002; Simoni-Wastila, 2004)
• Women prescribed opiates more often than men (Anthony, 2008; Gu, 2010; McCabe et al., 2005; Parsells, 2008; Roe, 2003; Zhong 2013)
• More chronic pain (Wiesenfeld-Hallin, 2005)
• Lower pain tolerance (Berkley, 1997; Dixon et al., 2004)
14
Heroin
• Men still more likely
to use heroin but
women’s use
rapidly rising o Men and women
equally likely to
inject
15
Injection Drug Use
• Injection drug use in particular related to partner
drug use (Powis et al. 1996)
• Women who inject heroin often have partner
who also injects
• Women more likely to be introduced to injection
by male partner
• Women more likely to share needles, leading to
higher risk of infection (Maher et al. 2006)
16
Telescoping
• A faster course from commencing substance use
to SUD and treatment onset
• More rapid progression of the disease – more
drug-related problems, sooner
• Several studies indicate a telescoping course for
women with OUD
17
Treatment
• Women less likely to go to treatment compared to
men
• Gender not predictive of LOS or outcome (Greenfield et al., 2007)
18
Children: Barrier to Treatment
• Women more likely to have children to care for (Bawor et al., 2015)
• Barriers to treatment
• Who will care for children while mother is in treatment?
• Many worry about custody issues (Greenfield et al., 2010)
• Mothers who are primary caretakers of the children may leave treatment early or not go at all due to childcare restraints (Castillo & Waldorf, 2008)
19
Children: Motivator for Treatment
• Evidence that women who live with their children
more likely to go to treatment (Greenfield et al., 2010)
• Women who are able to have children with them
in treatment or maintain custody, more likely to
stay in treatment (Greenfield et al., 2010)
20
Other Barriers
• Women often caretakers, both at home and in
caretaking professional roles (nurses, social
services, etc.)
• Women in leadership roles at home and at work
• It can be a difficult role-shift to ask for help, accept
help
• Shame
▪ Associated with relapse among women (Wiechelt &
Sales, 2001)
21
Question
How to motivate women to seek and sustain
treatment?
• Whenever possible, reducing practical barriers
including childcare
• Motivation to seek treatment:
▪ Often from primary care, welfare and other
community agencies
▪ A non-judgmental approach allows women to
be more open, reduce shame and stigma
22
Question
• Motivation to sustain treatment
• Motivational Interviewing
▪ Strengthen patient’s own motivation to change
▪ Elicit and encourage “change talk”
▪ OARS
▪ Non-confrontational, compassionate,
collaborative
23
Question
When should children be removed from
home/parent?
• Safety of child
• Move to a safe family member if possible
• Consult with experts in social work and/or law
24
Case Example
• 32 y/o single mother of 5 y/o boy and 3 y/o girl
• Father of children is in prison
• Patient is charged with attempting to sell drugs
from her car while children are in the backseat
• Patient is mandated to treatment
• Children to live with patient’s mother
• Patient’s mother becomes legal guardian
• At least 6 months sobriety required to reassess
25
Medication Treatment
• Medication: Methadone, Buprenorphine,
Naltrexone
• Consider gender-specific issues
• Different opioid binding capacity
• Hormone levels
26
Psychosocial Treatment
• In early recovery:
▪ Coping skills, problem-solving
▪ Meditation and breathing techniques
▪ Psychoeducation
• Motivational Interviewing
• Cognitive Behavioral Therapy
• Relapse Prevention
• Couples and Family
27
Question
• Are there structured support groups for
recovering women?
• AA/NA women’s groups
• Women’s groups at specific treatment centers
28
Co-occurring Conditions
• Compared to men, women with OUD more likely to
have:
▪ More physical health problems
▪ Family history of psychiatric illness
▪ Co-occurring psychological distress compared to
men (Back, 2010; Green et al., 2009)
29
Psychiatric Comorbidity
• Anxiety Disorders
▪ PTSD, OCD
• Mood Disorders
▪ Major depression
▪ Dysthymia
▪ Manic Disorder (Grella et al., 2009)
• Eating Disorders
▪ Bulimia
▪ Disordered eating
• Borderline Personality Disorder
30
Co-Occurring Disorders Treatment
• Many symptoms of acute and post-acute withdrawal
are also common to other mental health conditions:
▪ Anxiety, nervousness
▪ Insomnia
▪ Depressed mood
▪ Difficulty concentrating
• Important for treating clinician to differentiate and treat
appropriately
31
Maternal Opioid Use is Increasing
• Opiate use among pregnant women
▪ 1.19 (2000) to 5.63 (2009) per 1000 hospital
births per year
• Neonatal Abstinence Syndrome
▪ 1.20 (2000) to 3.39 (2009) per 1000 hospital
births per year (Patrick et al., 2012)
32
Heroin During Pregnancy
• Heroin use during pregnancy associated with
many adverse effects on fetus
▪ Short half-life, effects may be due to repeated
withdrawal in the fetus
• Take into account lifestyle effects of some women
actively using heroin
▪ Prostitution, theft, violence, STI’s
33
Treatment of Pregnant Women
• Opioid withdrawal should be avoided in pregnant
women
• Goals of MAT in pregnant women:
▪ Reduce risks of illicit opioid use and withdrawal
▪ Encourage prenatal care and treatment
▪ Reduce criminal activity
▪ Avoid associated risks
34
MOTHER Study
• Jones et al. 2012
• Methadone vs. buprenorphine in pregnant women
• Outcomes:
▪ Buprenorphine has similar maternal outcomes
to methadone
▪ Buprenorphine resulted in less severe
neonatal abstinence syndrome
35
Opioid Rx in Pregnant Women
If an opioid dependent pregnant woman is…
Stable on single agent
buprenorphine
Remain on single agent buprenorphine
Stable on Suboxone
Switch to single agent buprenorphine
Stable on methadone
Remain on methadone*
Naïve to agonist therapy
Consider buprenorphine due to lower NAS
severity
*unless reason to switch to buprenorphine, e.g., moving to location without
access to methadone clinic
Risk of precipitated withdrawal, vulnerability to illicit drug use
36
Opioid Rx in Pregnant Women
• Always consider full medical and psychological
history
• Assess dosage throughout pregnancy and adjust
as necessary
Inadequate dose may lead to withdrawal
symptoms, fetal distress, vulnerability to use
illicit drugs
37
Question
Please discuss the connection between opiate
medication combined with the epidural during
childbirth and previous and/or future addiction.
38
Analgesia During Labor
• Women on methadone or buprenorphine should
be offered analgesia options (epidural/spinal
anesthesia)
▪ Maintenance dose not adequate for pain relief
▪ Avoid agonist-antagonist
− may precipitate withdrawal
− Women taking methadone should not be
given buprenorphine
39
Analgesia During Labor
• Higher dose often needed for women on
maintenance medication
• Continue regular daily dose of maintenance
medication to prevent withdrawal
• Breastfeeding safe and encouraged
Minimal levels of methadone and
buprenorphine in breast milk
40
Question: OUD and Pain
• OUD and chronic pain commonly co-occur
• Women have:
More chronic pain (Wiesenfeld-Hallin, 2005)
Lower pain tolerance (Berkley, 1997; Dixon et al., 2004)
• Opiate pain medication should be avoided
• For individuals on maintenance medication, in the
case of surgery, medical team should be notified
and plan formulated
41
OUD and Pain
• Effective, non-pharmacological treatments for pain
▪ Psychoeducation
▪ Mindfulness exercises
▪ CBT
− cognitive restructuring
− activity pacing
▪ Grounding
42
Summary
• Women progress from first use to problem use
faster than men
• Women more likely to have co-occurring physical
or mental health condition
• Despite faster course, faster time to develop
problems associated with opioid use, and more
co-occurring disorders, women less likely to enter
treatment compared to men
• Gender is not predictive of LOS or outcome
43
Summary
• Must take into account co-occurring disorders
• Special considerations for pregnant women
44
Additional Questions
Could you address using while on methadone?
• Different treatment programs address this
differently
• Total abstinence vs. harm reduction
• May indicate need for higher LOC
45
Additional Questions
Info on changing standards for prescribing opioids.
• CDC Guideline for Prescribing Opioids for
Chronic Pain — United States, 2016
Recommendations and Reports / March 18,
2016 / 65(1);1–49
• http://www.cdc.gov/mmwr/volumes/65/rr/rr650
1e1.htm
46
Additional Questions
What are the studies identifying about the relapse
statistics after a methadone maintenance program?
• According to California Society of Addiction
Medicine, methadone maintenance success
rates range from 60 - 90%
• Longer time in treatment, better outcomes
• Best outcomes when combine medication with
psychosocial treatment
47
References
• Anthony M, Lee KY, Bertram CT, Abarca J, Rehfeld RA, Malone DC, ... Woosley RL (2008). Gender and age differences in medications dispensed from a national chain drugstore. Journal of Women's Health, 17(5): 735-743. • Back SE, Lawson KM, Singleton LM, Brady KT (2011). Characteristics and correlates of men and women with prescription opioid dependence. Addictive Behaviors, 36: 829 – 834. • Back S., Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L., ... Lin W (2011). Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.The American journal of drug and alcohol abuse, 37(5): 313-323. • Bawor M., Dennis BB, Varenbut M, Daiter J, Marsh DC, Plater C, ... Desai D. (2015). Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biology of sex differences, 6(1): 1-11. • Berkley KJ.(1997). Sex differences in pain. Behavioral and Brain Sciences, 20:371–380. • Bernstein J, Derrington TM, Belanoff C, Cabral HJ, Babakhanlou-Chase H, Diop H, ... Kotelchuck M (2015). Treatment outcomes for substance use disorder among women of reproductive age in Massachusetts: A population-based approach. Drug and alcohol dependence, 147: 151-159. • Castillo DT, Waldorf VA (2008). Ethical issues in the treatment of women with substance abuse. The book of ethics: Expert guidance for professionals who treat addiction, 101-114. • Centers for Disease Control and Prevention (CDC). Prescribing Data. (2016, March 16). Retrieved April 10, 2016, from http://www.cdc.gov/drugoverdose/data/prescribing.html • Centers for Disease Control and Prevention (CDC). Prescription painkiller overdoses: a growing epidemic, especially among women (2013, July.) Retrieved April 11, 2016 from http://www.cdc.gov/vitalsigns/PrescriptionPainkillerOverdoses/index.html • Cicero TJ, Ellis MS, Surratt HL, Kurtz, SP (2014). The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA psychiatry, 71(7): 821-826. • Dixon KE, Thorn BE, Ward LC (2004). An evaluation of sex differences in psychological and physiological responses to experimentally-induced pain: a path analytic description. Pain, 112(1): 188-196. • Green TC, Grimes Serrano JM, Licari A, Budman SH, Butler SF. (2009). Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug and Alcohol Dependence, 102 (1-2): 65 – 73. • Greenfield SF, Back SE, Lawson K, Brady KT (2010). Substance Abuse in Women. Psychiatric Clinics of North America, 33: 339 – 355.
48
References
• Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK., ... Miele, G. M. (2007). Substance abuse treatment entry, retention, and outcome in women: A review of the literature. Drug and alcohol dependence, 86(1): 1-21. • Grella CE, Karno MP, Warda US, Niv N, Moore AA (2009). Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addictive behaviors, 34(6): 498-504. • Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief. 2010:1–8. • Hölscher F, Reissner V, Di Furia L, Room R, Schifano F, Stohler R, ... Scherbaum N (2010). Differences between men and women in the course of opiate dependence: is there a telescoping effect?. European archives of psychiatry and clinical neuroscience, 260(3): 235-241. • Isacson D, Bingefors K. (2002). Epidemiology of analgesic use: a gender perspective. European Journal of Anaesthesiology, 19: 5-15. • Jones HE, Finnegan LP, Kaltenbach K (2012). Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs, 72(6): 747-757. • Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL (2006). Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction, 101(10): 1499-1508. • McCabe, S, Knight JR, Teter CJ, Wechsler H. (2005). Non‐medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction, 100(1): 96-106. • Parsells KJ, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. (2008) Prevalence and characteristics of opioid use in the US adult population. Pain, 138: 507–513. • Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. (2012). Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. Jama,307(18): 1934-1940. • Peles E, Adelson M, Seligman Z, Bloch M, Potik D, Schreiber S (2014). Psychiatric comorbidity differences between women with history of childhood sexual abuse who are methadone-maintained former opiate addicts and non-addicts. Psychiatry research, 219(1): 191-197. • Peles E, Weinstein A, Sason A, Adelson M, Schreiber S. (2014). Stroop task among patients with obsessive-compulsive disorder (OCD) and pathological gambling (PG) in methadone maintenance treatment (MMT). CNS spectrums, 19(06): 509-518. •Roe CM, McNamara AM, Motheral BR. (2002). Gender- and age-related prescription drug use patterns. Annals of Pharmacotherapy, 36:30–39.
49
References
• Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, ... Haddox JD (2007). Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug and alcohol dependence, 90(1): 64-71. •Ross J, Ross J, Teesson M, Ross J, Teesson M, Darke S, ... Ross J. (2005). The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug and alcohol review, 24(5): 411-418. • Shah NG, Lathrop SL, Reichard RR, Landen MG (2007). Unintentional drug overdose death trends in New Mexico, USA, 1990-2005: Combinations of heroin, cocaine, prescription opioids and alcohol. Addiction, 103: 126 – 136. • Simoni-Wastila L. (2000). The use of abusable prescription drugs: the role of gender. Journal of women's health & gender-based medicine, 9(3): 289-297. • Simoni-Wastila L., Ritter G., Strickler G. (2004). Gender and other factors associated with the nonmedical use of abusable prescription drugs.Substance use & misuse, 39(1): 1-23. • Substance Abuse and Mental Health Services Administration, Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014. • Unger A, Jung E, Winklbaur B, Fischer, G. (2010). Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. Journal of addictive diseases, 29(2), 217-230. • Wiechelt SA, Sales E. (2001). The role of shame in women's recovery from alcoholism: The impact of childhood sexual abuse. Journal of Social Work Practice in the Addictions, 1(4): 101-116. • Wiesenfeld-Hallin Z. (2005). Sex differences in pain perception. Gender Medicine, 2:137–145 • Zhong W, Maradit-Kremers H, St. Stauver JL, Yawn BP, Ebbert JO, Roger VL (2013). Age and sex patterns of drug prescribing in a defined American population. Mayo Clinic Proceedings, 88: 697 – 707. • Zweben, J. E. (2003). Special issues in treatment: Women. Principles of addiction medicine, 3111: 569-580.
50
PCSS-O Colleague Support Program
and Listserv
• PCSS-O Colleague Support Program is designed to offer general information to health
professionals seeking guidance in their clinical practice in prescribing opioid
medications.
• PCSS-O Mentors comprise a national network of trained providers with expertise in
addiction medicine/psychiatry and pain management.
• Our mentoring approach allows every mentor/mentee relationship to be unique and
catered to the specific needs of both parties.
• The mentoring program is available at no cost to providers.
• Listserv: A resource that provides an “Expert of the Month” who will answer questions
about educational content that has been presented through PCSS-O project. To join
email: [email protected].
For more information on requesting or becoming a mentor visit:
www.pcss-o.org/colleague-support
51
PCSS-O is a collaborative effort led by American Academy of Addiction Psychiatry (AAAP) in
partnership with: Addiction Technology Transfer Center (ATTC), American Academy of Neurology
(AAN), American Academy of Pain Medicine (AAPM), American Academy of Pediatrics (AAP),
American College of Physicians (ACP), American Dental Association (ADA), American Medical
Association (AMA), American Osteopathic Academy of Addiction Medicine (AOAAM), American
Psychiatric Association (APA), American Society for Pain Management Nursing (ASPMN),
International Nurses Society on Addictions (IntNSA), and Southeast Consortium for Substance Abuse
Training (SECSAT).
For more information visit: www.pcss-o.org
For questions email: [email protected]
Twitter: @PCSSProjects
Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Opioid Therapies (grant no. 5H79TI025595) from SAMHSA. The
views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department
of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.